| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/14728214.2013.807339 |
| P698 | PubMed publication ID | 23725568 |
| P50 | author | Peggy L St Jacques | Q47849702 |
| P2093 | author name string | Filip Van den Bosch | |
| P2860 | cites work | Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis | Q21134808 |
| Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis | Q22299388 | ||
| Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4 | Q24538382 | ||
| Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis | Q28183279 | ||
| A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis | Q28267921 | ||
| The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis | Q28306666 | ||
| Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation | Q29614224 | ||
| The pathogenesis of rheumatoid arthritis | Q29614957 | ||
| EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. | Q33292103 | ||
| A candidate gene approach identifies the TRAF1/C5 region as a risk factor for rheumatoid arthritis | Q33299576 | ||
| A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial | Q33675468 | ||
| Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group | Q33885648 | ||
| Efficacy and safety of the human anti-IL-1β monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study | Q33953931 | ||
| Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis | Q34091087 | ||
| LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study | Q34096856 | ||
| Cytokine signaling in 2002: new surprises in the Jak/Stat pathway | Q34126053 | ||
| Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and α-enolase: implications for autoimmunity in rheumatoid arthritis | Q34137749 | ||
| Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial | Q34275637 | ||
| Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. | Q34317049 | ||
| IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6 | Q34521302 | ||
| The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. | Q34540035 | ||
| R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation | Q34562439 | ||
| Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study | Q34562870 | ||
| Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. | Q48421921 | ||
| Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis | Q49143365 | ||
| Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial | Q49218023 | ||
| Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis. | Q50793569 | ||
| Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. | Q53239672 | ||
| The role of interleukin–15 in T–cell migration and activation in rheumatoid arthritis | Q57232112 | ||
| Modelling the cost effectiveness of TNF- antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry | Q57751320 | ||
| Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis | Q58912330 | ||
| Oncostatin M induces angiogenesis and cartilage degradation in rheumatoid arthritis synovial tissue and human cartilage cocultures | Q59042714 | ||
| Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study | Q34619338 | ||
| HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20 low expressing tumor cells that resist rituximab-mediated lysis. | Q34623592 | ||
| Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial | Q34651182 | ||
| IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial | Q34795777 | ||
| The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo | Q34989826 | ||
| Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial | Q35540009 | ||
| Detection of oncostatin M in synovial fluid from patients with rheumatoid arthritis | Q35547115 | ||
| Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis | Q35553008 | ||
| Chemokines in joint disease: the key to inflammation? | Q35553416 | ||
| A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate | Q35554448 | ||
| Chemokine and chemokine receptor expression in paired peripheral blood mononuclear cells and synovial tissue of patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis | Q35636896 | ||
| Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial | Q36084912 | ||
| Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial | Q36094059 | ||
| Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial) | Q36204088 | ||
| Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study | Q36610390 | ||
| The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons | Q36810833 | ||
| STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus | Q37070948 | ||
| Two independent alleles at 6q23 associated with risk of rheumatoid arthritis | Q37120830 | ||
| Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project | Q37568787 | ||
| The effect of biological agents on work participation in rheumatoid arthritis patients: a systematic review | Q37945576 | ||
| A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis | Q39763545 | ||
| Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial | Q39850979 | ||
| Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study | Q40377079 | ||
| CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study | Q40678725 | ||
| Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate | Q40678731 | ||
| Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis | Q42663487 | ||
| CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled clinical trial. | Q42943397 | ||
| Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial | Q42950968 | ||
| Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate | Q42956746 | ||
| Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis | Q43607170 | ||
| Amelioration of arthritis in two murine models using antibodies to oncostatin M. | Q43800699 | ||
| Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial | Q44165611 | ||
| Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks | Q44774931 | ||
| Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial | Q44985061 | ||
| A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. | Q45946407 | ||
| Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. | Q46019776 | ||
| Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. | Q46030933 | ||
| An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents | Q46066669 | ||
| Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial | Q46071397 | ||
| Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial | Q46271720 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| P304 | page(s) | 231-244 | |
| P577 | publication date | 2013-06-01 | |
| P1433 | published in | Expert Opinion on Emerging Drugs | Q5421207 |
| P1476 | title | Emerging therapies for rheumatoid arthritis | |
| P478 | volume | 18 |
| Q34533371 | A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy |
| Q33607501 | ADAMTS-12: a multifaced metalloproteinase in arthritis and inflammation |
| Q92422137 | Cartilage and Bone Destruction in Arthritis: Pathogenesis and Treatment Strategy: A Literature Review |
| Q38650245 | Combination Therapy of PEG-HM-3 and Methotrexate Retards Adjuvant-Induced Arthritis |
| Q34765802 | Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets |
| Q57557905 | Design, synthesis and evaluation of ()-3-(7-(methyl(7-pyrrolo[2,3-]pyrimidin-4-yl)amino)-5-azaspiro[2.4]heptan-5-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor |
| Q38233770 | Immune modulation by butyrophilins |
| Q38206551 | Investigational drugs for treating psoriatic arthritis |
| Q50900106 | Pharmacokinetics, Pharmacodynamics, and Safety of ASP015K (Peficitinib), a New Janus Kinase Inhibitor, in Healthy Subjects. |
Search more.